Synendos Therapeutics AG’s Post

Drug Discovery Services Market Worth $41.3 billion by 2028 🔵𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐑𝐄𝐄 𝐒𝐚𝐦𝐩𝐥𝐞:https://lnkd.in/diXdYs_N The global drug discovery services market in terms of revenue was estimated to be worth $20.6 billion in 2023 and is poised to reach $41.3 billion by 2028, growing at a CAGR of 14.9% from 2023 to 2028. 🔵 𝐌𝐚𝐢𝐧 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: @Drug Discovery and Development Centre (H3D), University of Cape Town        @Drug Discovery Unit, University of Dundee        Drug Discovery Innovation Programme (DDIP)    Drug Discovery Biology Strategy Meeting     Collaborative Drug Discovery - CDD Vault   Dalriada Drug Discovery SB Drug Discovery Warren Center for Neuroscience Drug Discovery Discovery Partners International, Inc. 23andMe   MEDGENOME  Certara Exelixis Recursion Phenomenex    GeneDx  insitro    Luminex          Relay Therapeutics     D. E. Shaw Research      Gilson     Eikon Therapeutics Atomwise Ventana Medical Systems    Alector Frontier Medicines Sanford Burnham Prebys    GenScript ProBio    Invicro   ATCC Nimbus Therapeutics      Valo Health  Genesis Biotechnology Group    Cellarity Dewpoint Therapeutics     Southern Research Coriell Institute for Medical Research      Enanta Pharmaceuticals   NGM Biopharmaceuticals      Covaris

BridGene Biosciences, Inc. co-founders Ping Cao and Irene Yuan are featured in the current issue of Drug Development & Delivery. In the realm of drug discovery, two primary approaches take center stage: Phenotypic Drug Discovery (PDD) and Target-Based Drug Discovery (TDD). Each approach offers unique advantages and has contributed significantly to the development of novel therapeutic agents. In this context, BridGene’s Chemoproteomic platform IMTAC™ (Isobaric Mass-Tagged Affinity Characterization) has emerged as one of the most powerful technologies to seamlessly merge the benefits of PDD and TDD. By utilizing IMTAC, re­searchers can efficiently analyze the interactions between poten­tial drug compounds and cellular proteins, allowing for the identification and validation of target molecules associated with specific phenotypic responses. https://lnkd.in/e3jbvghd

I find Qingxin Li's article very insightful got fragment based drug discovery Fragment-based drug discovery (FBDD) is a powerful method to develop potent small-molecule compounds starting from fragments binding weakly to targets. As FBDD exhibits several advantages over high-throughput screening campaigns, it becomes an attractive strategy in target-based drug discovery. Many potent compounds/inhibitors of diverse targets have been developed using this approach. Methods used in fragment screening and understanding fragment-binding modes are critical in FBDD. This review elucidates fragment libraries, methods utilized in fragment identification/confirmation, strategies applied in growing the identified fragments into drug-like lead compounds, and applications of FBDD to different targets. As FBDD can be readily carried out through different biophysical and computer-based methods, it will play more important roles in drug discovery. Read more: https://lnkd.in/dhjGPPmv Qingxin Li

BridGene Biosciences, Inc. co-founders Dr. Ping Cao and Irene Yuan write about chemoproteomics and the challenges of drugging undruggable targets in the January-February issue of Drug Development & Delivery magazine. #undruggabletargets #chemoproteomics DRUG DISCOVERY - Overcoming Traditional Challenges: Innovative Chemoproteomics Strategies to Revolutionize Drug Discovery (drug-dev.com)

Can you go from idea to drug candidate in one year? At Gubra, we constantly pursue novel approaches to advance and enable smarter and faster peptide drug discovery. Therefore, we were eager to get started when presented with this exciting challenge “can you make a drug candidate that ticks all the boxes, i.e. potent in vivo efficacy, a long half-life and excellent physicochemical properties. Do it within a year!” With this aim, we exploited our innovative ML-based peptide drug discovery platform ‘streaMLine’ and demonstrated how the platform effectively facilitates accelerated development of novel peptide-based therapeutics. Did we succeed? Yes! And it has been a fun ride! Definitely some ups and downs along the way and many lengthy discussions with the project team. A total of 2688 peptides were synthesized, screened, and analyzed using the ML-guided approach to map out a solution space for generating GLP-1R agonists derived from the secretin backbone. We are happy to present the inner workings of our streaMLine drug discovery platform in the Journal of Medicinal Chemistry Kudos to the amazing team, (Jens Christian Nielsen,Claudia U. Hjørringgaard,Mads Mørup Nygaard, Anita Wester, Lisbeth Elster, Trine Porsgaard, Randi Bonke Mikkelsen, Silas Anselm Rasmussen, Andreas Nygaard Madsen, Morten Schlein, Niels Vrang, Kristoffer Rigbolt). Thanks for making this project a success. If you are into some light summer reading, you can find the full story here: (https://lnkd.in/dsAm7UHE) #drugdiscovery #pushingboundaries #speed #quality

"Today’s drug discovery favors precision drug therapy, push­ing complex modalities like combination therapies and biologics, along with cell- and gene-based therapeutics to the forefront. Major advances in areas, such as synthetic biology, advanced dis­ease model creation, and integrated multi-omics-based work­flows, continue to evolve our understanding of human pathophysiologies and bring the hope of new treatments to the market with an ever-increasing speed. Aside from being intricate, they are also lengthy processes with greater risks for human error." John Fuller, Commercial Product Manager, discusses with Drug Development & Delivery solutions to alleviate bottlenecks and streamline workflows in drug discovery through acoustic liquid handling: https://lnkd.in/epVC_e6A #LiquidHandling #DrugDiscovery #BECLSnews #InTheNews

Two must-attend sessions at the Oligonucleotide Therapeutics Xchange - Maryland 2024, 30 October, that you won't want to miss! Secure your free pass: https://lnkd.in/eWms8KbQ 🎯 Sponsor-led Roundtable Discussion: "Manufacturing n-of-1 Batches - Helping 1 Patient at a Time?" ⏰ 11:25 AM - 12:25 PM Join us for a sponsor-led roundtable discussion where we'll delve into the intricacies of manufacturing n-of-1 batches—a groundbreaking approach that could revolutionize personalized medicine, one patient at a time. This is a unique opportunity to engage with industry experts, exchange ideas, and explore innovative strategies in oligonucleotide manufacturing. 🎤 Poster Presentation: "Thiophosphoramidate Morpholino Oligonucleotides (TMOs): A Novel Class of PMOs Compatible With Conventional Automated Oligonucleotide Synthesis" ⏰ 3:15 PM - 3:45 PM Presented by Jeremy Little, Director of Custom Oligonucleotides at ChemGenes this session will showcase the latest advancements in TMOs—a novel class of PMOs that are set to enhance oligonucleotide synthesis. With over a decade of experience in nucleic acid drug discovery and oligonucleotide manufacturing, Jeremy brings unparalleled expertise to the table. Whether you're involved in biotech, pharma, or are just passionate about the future of oligonucleotide therapeutics, these sessions are invaluable. 💊Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. #LifeSciences #PrecisionMedicine #NucleicAcids #Pharmaceuticals #MedicalInnovation #Healthcare #Biotechnology #DrugDevelopment #MolecularBiology #ScientificResearch #GeneTherapy #OligonucleotideSynthesis #Biopharma #FutureOfMedicine #BiotechIndustry #InnovationInHealthcare #PharmaResearch #MedicinalChemistry #ClinicalResearch #ScientificRoundtable #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

AI can beat grandmasters at chess and outwit the world’s best at Go – but is it better than humans at coming up with new drugs? We speak to Dr Dave H. (Exscientia Chief Scientific Officer and Interim CEO) and Dr Alex Zhavoronkov (Insilico Medicine Founder and CEO) about their work revolutionising drug discovery: https://hubs.la/Q02vkX_q0 #artificialintelligence #AI #drugdiscovery #bioinformatics #computationalbiology #pharma #biotech Also mentioned: Sumitomo Pharma Co., Ltd., Sanofi, Bristol Myers Squibb, Merck Group, Bill & Melinda Gates Foundation, Relay Therapeutics, Nimbus Therapeutics, Healx, Google DeepMind

Over a quarter of a billion dollars for cyclic peptide-based drugs🚀 It's an exciting time for peptides. Unnatural Products, Insamo, and recently founded Orbis Medicine collected $260 million to discover and help develop novel cyclic peptide drugs. And that's just a glimpse from the previous two months... This is your chance to catch up and understand the behind-the-scenes peptide science. Join us for a webinar on March 21st featuring Dr. James Krupa, Principal Research Scientist at Charnwood Discovery. Dr. Krupa will delve into the intricacies of cyclic peptide synthesis and how the CRO utilizes cutting-edge technology to elevate capabilities in meeting complex project requirements. REGISTER HERE: https://lnkd.in/ehXtTKD8 In this session, you'll gain knowledge on: 👉🏽 Synthesis and cyclization tips for peptides 👉🏽 Identifying and managing issues related to ring strain in cyclic peptides 👉🏽 Strategies for understanding the Structure-Activity Relationship (SAR) of cyclic peptides 👉🏽 Exploring potential challenges in drug discovery with cyclic peptides Take advantage of this opportunity to grasp the challenges and strategies involved in synthesizing cyclic peptides and their crucial role in drug discovery. Register now! https://lnkd.in/ehXtTKD8   #peptide #synthesis #purepep 

Finally small molecules are doing big…. AZ is exploring the potential to use small molecule drugs to target RNA. Small molecule drugs have been the mainstay of the pharmaceutical industry for nearly a century. Defined as any organic compound with low molecular weight, small molecule drugs have some distinct advantages as therapeutics: most can be administered orally and they can pass through cell membranes to reach intracellular targets. They can also be designed to engage biological targets by various modes of action and their distribution can further be tailored, for example to allow for systemic exposure with or without brain penetration. Modulating biological disease driving pathways at the RNA level opens up new opportunities for previous undruggable targets